Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Starling

Showing results (131-140 of 155) with videos related to

Pageof 16
Sort By:
Journal of Medicinal Chemistry|March 1, 1989
New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activityB C Laguzza, C L Nichols, S L Briggs, et al.
Headache|December 14, 2020
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2Hans-Christoph Diener, Michael J Marmura, Stewart J Tepper, et al.
Cancer Research|December 1, 1990
In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugatesJ J Starling, R S Maciak, N A Hinson, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activitiesA H Dantzig, R L Shepard, K L Law, et al.
Molecular Cancer Therapeutics|August 15, 2014
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulationVipin Yadav, Teresa F Burke, Lysiane Huber, et al.
Cancer Research|December 4, 2001
Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancerN Suh, A L Glasebrook, A D Palkowitz, et al.
Diagnostics (Basel, Switzerland)|August 10, 2024
Baseline Normative and Test-Retest Reliability Data for Sideline Concussion Assessment Measures in YouthJennifer V Wethe, Jamie Bogle, David W Dodick, et al.
International Journal of Cancer|January 5, 2002
A very early induction of major vault protein accompanied by increased drug resistance in U-937 cellsYi Hu, Andrew G Stephen, Jin Cao, et al.
Neurology. Clinical Practice|February 13, 2018
King-Devick Test identifies real-time concussion and asymptomatic concussion in youth athletesPriya S Dhawan, Danielle Leong, Lisa Tapsell, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 1999
Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146B H Norman, A H Dantzig, J S Kroin, et al.
Pageof 16

Showing results (131-140 of 155) with videos related to

Sort By:
Pageof 16
Journal of Medicinal Chemistry|March 1, 1989
New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activityB C Laguzza, C L Nichols, S L Briggs, et al.
Headache|December 14, 2020
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2Hans-Christoph Diener, Michael J Marmura, Stewart J Tepper, et al.
Cancer Research|December 1, 1990
In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugatesJ J Starling, R S Maciak, N A Hinson, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activitiesA H Dantzig, R L Shepard, K L Law, et al.
Molecular Cancer Therapeutics|August 15, 2014
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulationVipin Yadav, Teresa F Burke, Lysiane Huber, et al.
Cancer Research|December 4, 2001
Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancerN Suh, A L Glasebrook, A D Palkowitz, et al.
Diagnostics (Basel, Switzerland)|August 10, 2024
Baseline Normative and Test-Retest Reliability Data for Sideline Concussion Assessment Measures in YouthJennifer V Wethe, Jamie Bogle, David W Dodick, et al.
International Journal of Cancer|January 5, 2002
A very early induction of major vault protein accompanied by increased drug resistance in U-937 cellsYi Hu, Andrew G Stephen, Jin Cao, et al.
Neurology. Clinical Practice|February 13, 2018
King-Devick Test identifies real-time concussion and asymptomatic concussion in youth athletesPriya S Dhawan, Danielle Leong, Lisa Tapsell, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 1999
Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146B H Norman, A H Dantzig, J S Kroin, et al.
Pageof 16